Русская версия English version   
О журнале
Редакционная коллегия
Правила для авторов
Информация для читателей и авторов
Оглавление текущего номера
Архив
Контакты
Поиск

Отправить статью
 


Том 19   Выпуск 2   Год 2024
Список литературы

  1. Nelson D.R. Cytochrome P450 nomenclature, 2004. In: Cytochrome P450 Protocols. Methods in Molecular Biology, vol. 320. Eds. Phillips I.R., Shephard E.A. Totowa, NJ: Humana Press, 2006. P. 1–10. doi: 10.1385/1-59259-998-2:1
  2. Nebert D.W., Russell D.W. Clinical importance of the cytochromes P450. The Lancet. 2002;360:1155–1162. doi: 10.1016/S0140-6736(02)11203-7
  3. Takahashi H., Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet. 2001;40:587–603. doi: 10.2165/00003088-200140080-00003
  4. Zanger U.M., Turpeinen M., Klein K., Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem. 2008;392:1093–1108. doi: 10.1007/s00216-008-2291-6
  5. Zanger U.M., Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 2013;138:103–141. doi: 10.1016/j.pharmthera.2012.12.007
  6. Miners J.O., Birkett D.J. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 1998;45:525–538. doi: 10.1046/j.1365-2125.1998.00721.x
  7. Gray I.C., Nobile C., Muresu R., Ford S., Spurr N.K. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics. 1995;28:328–332. doi: 10.1006/geno.1995.1149
  8. Lee C.R., Goldstein J.A., Pieper J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002;12:251–263. doi: 10.1097/00008571-200204000-00010
  9. Ged C., Umbenhauer D.R., Bellew T.M., Bork R.W., Srivastava P.K., Shinriki N., Lloyd R.S., Guengerich F.P. Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4’-hydroxylase. Biochemistry. 1988;27:6929–6940. doi: 10.1021/bi00418a039
  10. Stubbins M.J., Harries L.W., Smith G., Tarbit M.H., Wolf C.R. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics. 1996;6:429–439. doi: 10.1097/00008571-199610000-00007
  11. Sullivan-Klose T.H., Ghanayem B.I., Bell D.A., Zhang Z.Y., Kaminsky L.S., Shenfield G.M., Miners J.O., Birkett D.J., Goldstein J.A. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996;6:341–349. doi: 10.1097/00008571-199608000-00007
  12. Schwarz U.I. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur. J. Clin. Invest. 2003;33(2):23–30. doi: 10.1046/j.1365-2362.33.s2.6.x
  13. Si D., Guo Y., Zhang Y., Yang L., Zhou H., Zhong D. Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics. 2004;14:465–469. doi: 10.1097/01.fpc.0000114749.08559.e4
  14. McCrea J.B., Cribb A., Rushmore T., Osborne B., Gillen L., Lo M.W., Waldman S., Bjornsson T., Spielberg S., Goldberg M.R. Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clin. Pharmacol. Ther. 1999;65:348–352. doi: 10.1016/S0009-9236(99)70114-1
  15. Stearns R.A., Chakravarty P.K., Chen R., Chiu S.H. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab. Dispos. 1995;23:207–215.
  16. Kaukonen K.M., Olkkola K.T., Neuvonen P.J. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur. J. Clin. Pharmacol. 1998;53:445–449. doi: 10.1007/s002280050405
  17. Williamson K.M., Patterson J.H., McQueen R.H., Adams K.F.J., Pieper J.A. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin. Pharmacol. Ther. 1998;63:316–323. doi: 10.1016/S0009-9236(98)90163-1
  18. Goldberg M.R., Lo M.W., Bradstreet T.E., Ritter M.A., Höglund P. Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist. Eur. J. Clin. Pharmacol. 1995;49:115–119. doi: 10.1007/BF00192369
  19. Kobayashi M., Takagi M., Fukumoto K., Kato R., Tanaka K., Ueno K. The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan. Drug Metab. Pharmacokinet. 2008;23:115–119. doi: 10.2133/dmpk.23.115
  20. Wennerholm A., Nordmark A., Pihlsgård M., Mahindi M., Bertilsson L., Gustafsson L.L. Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo. Eur. J. Clin. Pharmacol. 2006;62:539–546. doi: 10.1007/s00228-006-0121-3
  21. Timmermans P.B., Wong P.C., Chiu A.T., Herblin W.F., Benfield P., Carini D.J., Lee R.J., Wexler R.R., Saye J.A., Smith R.D. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 1993;45:205–251.
  22. Yasar U., Tybring G., Hidestrand M., Oscarson M., Ingelman-Sundberg M., Dahl M.L., Eliasson E. Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab. Dispos. 2001;29:1051–1056.
  23. Yun C.H., Lee H.S., Lee H., Rho J.K., Jeong H.G., Guengerich F.P. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug Metab. Dispos. 1995;23:285–289.
  24. Lo M.W., Goldberg M.R., McCrea J.B., Lu H., Furtek C.I., Bjornsson T.D. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin. Pharmacol. Ther. 1995;58:641–649. doi: 10.1016/0009-9236(95)90020-9
  25. Yasar U., Forslund-Bergengren C., Tybring G., Dorado P., Llerena A., Sjöqvist F., Eliasson E., Dahl M.L. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin. Pharmacol. Ther. 2002;71:89–98. doi: 10.1067/mcp.2002.121216
  26. Karatza E., Karalis V. Modelling gastric emptying: A pharmacokinetic model simultaneously describing distribution of losartan and its active metabolite EXP-3174. Basic Clin. Pharmacol. Toxicol. 2020;126:193–202. doi: 10.1111/bcpt.13321
  27. Kolpakov F., Akberdin I., Kashapov T., Kiselev l., Kolmykov S., Kondrakhin Y., Kutumova E., Mandrik N., Pintus S., Ryabova A. et al. BioUML: an integrated environment for systems biology and collaborative analysis of biomedical data. Nucleic Acids Res. 2019;47:W225–W233. doi: 10.1093/nar/gkz440
  28. Kolpakov F., Akberdin I., Kiselev I., Kolmykov S., Kondrakhin Y., Kulyashov M., Kutumova E., Pintus S., Ryabova A., Sharipov R. et al. BioUML-towards a universal research platform. Nucleic Acids Res. 2022;50:W124–W131. doi: 10.1093/nar/gkac286
  29. Kiselev I.N., Semisalov B.V., Biberdorf E.A., Sharipov R.N., Blokhin A.M., Kolpakov F.A. Modular Modeling of the Human Cardiovascular System. Mathematical Biology and Bioinformatics. 2012;7(2):703–736. doi: 10.17537/2012.7.703
  30. Kutumova E.O. Reduction of the Model of CD95-induced Apoptosis. Mathematical Biology and Bioinformatics. 2012;7(1):139–151. doi: 10.17537/2012.7.139
  31. Kutumova E.O., Zinovyev A.Y., Sharipov R.N., Kolpakov F.A. The Application of Model Reduction Methods to the Construction of the Composite Model of Apoptotic Pathways. Mathematical Biology and Bioinformatics. 2012;7(2):572–588. doi: 10.17537/2012.7.572
  32. Kiselev I.N., Biberdorf E.A., Baranov V.I., Komlyagina T.G., Melnikov V.N., Suvorova I.Yu., Krivoshchekov S.G., Kolpakov F.A. Personalization of Parameters and Validation of Model of the Human Cardiovascular System. Mathematical Biology and Bioinformatics. 2015;10(2):526–547. doi: 10.17537/2015.10.526
  33. Kiselev I.N., Kutumova E.O., Kolpakova A.F., Lifshits G.I., Kolpakov F.A. Mathematical Modeling of the Antihypertensive Drugs Action. Mathematical Biology and Bioinformatics. 2019;14(1):233–256. doi: 10.17537/2019.14.233
  34. Kiselev I.N., Akberdin I.R., Vertyshev A.Yu., Popov D.V., Kolpakov F.A. A Modular Visual Model of Energy Metabolism in Human Skeletal Muscle. Mathematical Biology and Bioinformatics. 2019;14(2):373–392. doi: 10.17537/2019.14.373
  35. Akberdin I.R., Vertyshev A.Yu., Pintus S.S., Popov D.V., Kolpakov F.A. A Mathematical Model Linking Ca2+-Dependent Signaling Pathway and Gene Expression Regulation in Human Skeletal Muscle. Mathematical Biology and Bioinformatics. 2020;15(1):20–39. doi: 10.17537/2020.15.20
  36. Borodulina A.D., Kutumova E.O., Lifshits G.I., Kolpakov F.A. Mathematical Modeling of Antihypertensive Therapy with Azilsartan Medoxomil on the Example of Clinical Data of a Real Patient. Mathematical Biology and Bioinformatics. 2023;18(1):228–250. doi: 10.17537/2023.18.228
  37. Kondrakhin P.Y., Kolpakov F.A. Multilevel Mathematical Model of Epileptic Seizures. Mathematical Biology and Bioinformatics. 2023;18(2):479–516. doi: 10.17537/2023.18.479
  38. Keating S.M., Waltemath D., König M., Zhang F., Dräger A., Chaouiya C., Bergmann F.T., Finney A., Gillespie C.S., Helikar T. et al. SBML Level 3: an extensible format for the exchange and reuse of biological models. Mol. Syst. Biol. 2020;16:e9110. doi: 10.15252/msb.20199110
  39. Malik-Sheriff R.S., Glont M., Nguyen T.V.N., Tiwari K., Roberts M.G., Xavier A., Vu M.T., Men J., Maire M., Kananathan S. et al. BioModels-15 years of sharing computational models in life science. Nucleic Acids Res. 2020;48:D407–D415. doi: 10.1093/nar/gkz1055
  40. Runarsson T., Yao X. Yao, X.: Stochastic ranking for constrained evolutionary optimization. IEEE Trans. Evol. Comput.  2000;4:284–294. doi: 10.1109/4235.873238
  41. Bjorkman M., Holmström K. Global optimization using the DIRECT algorithm in Matlab. Adv. Model. Optim. 2004;1.
  42. Goldfeld S.M., Quandt R.E., Trotter H.F. Maximization by Quadratic Hill-Climbing. Econometrica. 1966;34:541–551. doi: 10.2307/1909768
  43. Sierra M.R., Coello C.A.C. Improving PSO-Based Multi-objective Optimization Using Crowding, Mutation and epsilon-Dominance. In International Conference on Evolutionary Multi-Criterion Optimization. 2005. doi: 10.1007/978-3-540-31880-4_35
  44. Nebro A.J., Durillo J.J., Luna F., Dorronsoro B., Alba E. MOCell: A cellular genetic algorithm for multiobjective optimization. Int. J. Intell. Syst. 2009;24. doi: 10.1002/int.20358
  45. Ingber L. Adaptive simulated annealing (ASA): Lessons learned. Control Cybern. 1996;25:33–54. doi: Cite to nonCR doi: 10.48550/arXiv.cs/0001018
  46. Raue A., Kreutz C., Maiwald T., Bachmann J., Schilling M., Klingmüller U., Timmer J. Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood. Bioinformatics. 2009;25:1923–1929. doi: 10.1093/bioinformatics/btp358
  47. Raue A., Becker V., Klingmüller U., Timmer J. Identifiability and observability analysis for experimental design in nonlinear dynamical models. Chaos Woodbury N. 2010;20:045105. doi: 10.1063/1.3528102
  48. Rabitz H.A., Kramer M.A., Dacol D.K. Sensitivity Analysis in Chemical Kinetics. Annu. Rev. Phys. Chem. 1983;34:419–461. doi: 10.1146/annurev.pc.34.100183.002223
  49. Toutain P.L., Bousquet-Mélou A. Plasma terminal half-life. J. Vet. Pharmacol. Ther. 2004;27:427–439. doi: 10.1111/j.1365-2885.2004.00600.x
  50. Le Novère N., Hucka M., Mi H., Moodie S., Schreiber F., Sorokin A., Demir E., Wegner K., Aladjem M.I., Wimalaratne S.M. et al. The Systems Biology Graphical Notation. Nat. Biotechnol. 2009;27:735–741. doi: 10.1038/nbt.1558
  51. Deloose E., Janssen P., Depoortere I., Tack J. The migrating motor complex: control mechanisms and its role in health and disease. Nat. Rev. Gastroenterol. Hepatol. 2012;9:271–285. doi: 10.1038/nrgastro.2012.57
  52. Feher J. Intestinal and Colonic Chemoreception and Motility. 2017:796–809. doi: 10.1016/B978-0-12-800883-6.00079-3
  53. Dominiczak A.F., Negrin D.C., Clark J.S., Brosnan M.J., McBride M.W., Alexander M.Y. Genes and hypertension: from gene mapping in experimental models to vascular gene transfer strategies. Hypertens. Dallas Tex. 1979. 2000;35:164–172. doi: 10.1161/01.HYP.35.1.164
  54. Menni C., Mangino M., Zhang F., Clement G., Snieder H., Padmanabhan S., Spector T.D. Heritability analyses show visit-to-visit blood pressure variability reflects different pathological phenotypes in younger and older adults: evidence from UK twins. J. Hypertens. 2013;31:2356–2361. doi: 10.1097/HJH.0b013e32836523c1
  55. Chavda H., Patel C., Anand I.S. Biopharmaceutics Classification System. Syst. Rev. Pharm. 2010;1:62–69. doi: 10.4103/0975-8453.59514
  56. Sugihara M., Takeuchi S., Sugita M., Higaki K., Kataoka M., Yamashita S. Analysis of Intra- and Intersubject Variability in Oral Drug Absorption in Human Bioequivalence Studies of 113 Generic Products. Mol. Pharm. 2015;12:4405–4413. doi: 10.1021/acs.molpharmaceut.5b00602
  57. Tsume Y., Amidon G.L. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation. Mol. Pharm. 2010;7:1235–1243. doi: 10.1021/mp100053q
  58. Higaki K., Choe S.Y., Löbenberg R., Welage L.S., Amidon G.L. Mechanistic understanding of time-dependent oral absorption based on gastric motor activity in humans. Eur. J. Pharm. Biopharm. 2008;70:313–325. doi: 10.1016/j.ejpb.2008.02.022
  59. Langguth P., Lee K.M., Spahn-Langguth H., Amidon G.L. Variable gastric emptying and discontinuities in drug absorption profiles: dependence of rates and extent of cimetidine absorption on motility phase and pH. Biopharm. Drug Dispos. 1994;15:719–746. doi: 10.1002/bdd.2510150902
  60. Oberle R.L., Amidon G.L. The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J. Pharmacokinet. Biopharm. 1987;15:529–544. doi: 10.1007/BF01061761
  61. Takamatsu N., Welage L.S., Hayashi Y., Yamamoto R., Barnett J.L., Shah V.P., Lesko L.J., Ramachandran C., Amidon G.L. Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans: correlation with antral gastric motility. Eur. J. Pharm. Biopharm. 2002;53:37–47. doi: 10.1016/S0939-6411(01)00207-7
  62. Shin H.-B., Jung E.H., Kang P., Lim C.W., Oh K.-Y., Cho C.-K., Lee Y.J., Choi C.-I., Jang C.-G., Lee S.-Y. et al. ABCB1 c.2677G>T/c.3435C>T diplotype increases the early-phase oral absorption of losartan. Arch. Pharm. Res. 2020;43:1187–1196. doi: 10.1007/s12272-020-01294-3
Содержание
Оригинальная статья
Бабаев Д.С., Кутумова Е.О., Колпаков Ф.А. Моделирование дифференциального влияния аллелей гена CYP2C9 на метаболизм лозартана. Математическая биология и биоинформатика. 2024;19(2):533-564. doi: 10.17537/2024.19.533
(опубликована на рус. яз.)

Аннотация (рус.)
Аннотация (англ.)
Полный текст (рус., pdf)
Список литературы

 
  Copyright ИМПБ РАН © 2005-2026